TG Therapeutics price target raised to $24 from $19 at H.C. Wainwright

H.C. Wainwright analyst Edward White raised the firm’s price target on TG Therapeutics to $24 from $19 and reiterates a Buy rating on the shares. The FDA approved Briumvi, TG’s novel glycoengineered anti-CD20 monoclonal antibody, for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults, White tells investors in a research note. The analyst believes a faster infusion time could enable Briumvi to "quickly gain share." In addition, "there could be a large opportunity in this indication for a small disruptive sales force," contends White.